![2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carbo…](https://static.cymitquimica.com/products/3D/img/FM102909.png "Cliccare per ingrandire")
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid
CAS: 1372540-25-4
Rif. 3D-FM102909
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione |
Informazioni sul prodotto
Nome:
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid
Descrizione:
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid (BIC) is a strain that is categorized as a cancer drug. It has been synthesized in the laboratory and has been shown to bind to the bRaf protein, inhibiting its activity. BIC is also known as a stereoisomer because it has two different forms, L and D. The symbol for this drug is "BIC". This drug discriminates between healthy cells and cancer cells by selectively targeting those with mutated bRaf proteins. The parameter of this drug that is quantized is its effect on cancer cells. BIC's virulent effects may be due to its ability to inhibit the synthesis rate of antibodies in the body.
Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:
Proprietà chimiche
Peso molecolare:
433.42 g/mol
Formula:
C22H22F3N3O3
Purezza:
Min. 95%
MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:
